Lyra Health
Lyra Health provides workforce mental health benefits through a digital platform featuring AI-powered provider matching and personalized support.
Secondary Market Price
Secondary Market Price
How Lyra Health Measures Up
To help you manage your Lyra Health equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series G
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Lyra Health's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Lyra Health Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Lyra Health's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Lyra Health is a provider of workforce mental health benefits, serving more than 17 million people across the globe. The company operates a digital platform that uses AI-powered technology to match individuals with a network of mental health providers for services like therapy, coaching, and medication management. Founded in 2015 and headquartered in Burlingame, California, Lyra Health has grown to approximately 2,698 employees. The company is privately held and has raised over $905 million in funding, with its most recent Series F round in February 2022 securing $235 million.
The company's future plans include continued global expansion and innovation in its digital health platform. Lyra Health focuses on helping employers create well-being programs that support employee resilience. Recent company activities include the publication of its 2026 Workforce Mental Health Trends Report, which offers strategies for organizations to support their employees. The company also shared a testimonial from a notable client, Heidelberg Materials North America, highlighting the accessibility of Lyra's services for its 7,000 employees.
- Addition
- Adams Street Partners
- Howard Schultz
- Casdin Capital
- Glynn Capital
- Greylock Partners
- IVP
- Meritech Capital Partners
- Providence Ventures
- Tenaya Capital
- Dragoneer Investment Group
- Salesforce Ventures
- Coatue Management
- Durable Capital Partners LP
- Fidelity Management & Research Company
- Baillie Gifford
- Sands Capital
- Breyer Capital
- Crown Venture Fund
- Venrock
- Co-Founder, David Ebersman
- Co-Founder, Bob Kocher
- Co-Founder, Dena Bravata
- Co-Founder, Bryan Roberts
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Lyra Health worth joining?
Deciding if Lyra Health is worth joining depends on your personal career goals and whether the company is a good fit for you. When considering the compensation, platforms like Prospect can help you analyze the potential value of your equity grant to make a more informed decision.
What should I do with my Lyra Health stock?
The best strategy for your Lyra Health stock depends on your personal financial goals, such as diversifying your investments or needing liquidity for a large purchase. Platforms like Prospect can help you create a personalized plan by modeling different scenarios and providing tax-optimized recommendations for your shares.
Can you sell Lyra Health stock?
Yes, it is often possible to sell shares of a private company like Lyra Health through secondary markets or in company-approved tender offers. Tools like Prospect offer tender offer tools to help you navigate these sales by determining which shares are most tax-optimal to sell.
How can I find the value of my Lyra Health stock?
The value of private stock is typically determined by a company's 409A valuation, the price of its most recent funding round, or transactions on secondary markets. You can get a clearer picture of its potential future value using platforms like Prospect, which uses predictive models and market data to help forecast your equity's worth.
What is Lyra Health's equity worth?
The exact worth of private company equity like Lyra Health's is not public information and fluctuates based on company performance and market conditions. To understand what your specific holdings could be worth, you can use platforms that provide future price projections and allow you to model various financial scenarios.
What is Lyra Health's stock ticker symbol?
As a private company, Lyra Health is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies when they go public through an Initial Public Offering (IPO).
Can I buy or sell Lyra Health stock?
Selling private stock like Lyra Health's is often possible through secondary markets or tender offers, while buying is typically restricted to accredited investors or employees exercising options. Platforms like Prospect are designed to help current equity holders manage and optimize the sale of their shares, not to facilitate new investments.
What is the criteria to buy or invest in Lyra Health stock?
Investing in a private company like Lyra Health is generally limited to employees receiving equity compensation or accredited investors participating in funding rounds or secondary market purchases. Opportunities for the general public to invest are typically unavailable until the company holds an Initial Public Offering (IPO).
